Release Date: April 2016
Number of Pages: 223
Number of Tables and Figures: 52
Synopsis: Often cited as one of the leading causes of death worldwide, cancer refers to a group of diseases that are characterized by unrestrained or unregulated growth of cells leading to the formation of malignant tumors that can invade other parts of the body and eventually impair normal functions.
The prevalence of cancer is continuing to grow, with approximately 15 Million new cases globally each year. However, several immunotherapy and targeted treatments have significantly improved patient outcomes and survival rates. The market is ripe for future growth with a number of targeted therapies in late-stage development, such as PD-1/PD-L1 inhibitors.
As new drugs continue to revitalize the cancer treatment ecosystem, we expect the cancer drugs market to grow at a CAGR of 9% between 2016 and 2020, eventually accounting for nearly $120 Billion in revenue.
The “Cancer Drugs Market: 2016 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the cancer drugs ecosystem including treatment options, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for cancer drugs from 2016 through to 2030. The forecasts are segmented for 2 therapeutic pathways, 11 therapeutic categories, 5 regions and 25 leading countries.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.
Company Wide License (Global Site): USD 6,500
For a sample of the report or any further inquiries please contact firstname.lastname@example.org
Pricing: The report is available for the following price:
Single User License: USD 2,500
Company Wide License (Single Site): USD 3,500
The report has the following key findings:
The report covers the following topics:
Historical Revenue & Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
Key Questions Answered:
The report provides answers to the following key questions:
List of Companies Mentioned:The following companies and organizations have been reviewed, discussed or mentioned in the report:
BMS (Bristol-Myers Squibb)
CTI Biopharma Corporation
Dr. Reddy's Laboratories
Eli Lilly & Company
Janssen Pharmaceutical Companies
Johnson & Johnson
Les Laboratoires Servier
Massachusetts General Hospital
Merck & Co.
MIT (Massachusetts Institute of Technology)
NHS (National Health Service, UK)
NTU (Nanyang Technological University)
Roche Holding (F. Hoffmann-La Roche)
Sumitomo Dainippon Pharma
Sun Pharma (Sun Pharmaceutical Industries)
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries
U.S. FDA (Food and Drug Administration)
United Therapeutics Corporation